Question · Q3 2025
Joanna asked about the wide $0.35 EPS guidance range for 2025, seeking clarification on the major moving pieces that could lead to the high or low end of that range.
Answer
Chairman and CEO Adam Schechter explained that while revenue and diagnostic guidance ranges were narrowed, the biopharma laboratory services (BLS) range was purposely kept wider. This is due to the inherent uncertainty in the timing of divestitures and site consolidation actions planned for the early development business, which could impact the current quarter.